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Abstract We describe a 15-year-old patient with X-linked
agammaglobulinemia who developed malabsorption and
bacteremia due to infection of Helicobacter pylori and
Campylobacter jejuni. The Campylobacter bacteremia was
only recognized after subculturing of blood culture bottles
that failed to signal in the automated system. After 2 weeks
of treatment with meropenem and erythromycin for
4 weeks, the patient developed a relapse of bacteremia
10 months later with a high level erythromycin resistant C.
jejuni. Sequencing revealed an A2058C mutation in the 23
S rRNA gene associated with this resistance. Treatment
with doxycycline for 4 weeks finally resulted in complete
eradication. This case report illustrates the importance for
physicians to use adapted culture methods and adequate
prolonged therapy in patients with an immunodeficiency. A
summary of published case reports and series of patients
with hypogammaglobulinemia or agammaglobulinemia
with Campylobacter or Helicobacter bacteremia is given.
Introduction
X-linked agammaglobulinemia (XLA) is a primary immu-
nodeficiency caused by a mutation in the Bruton Tyrosine
Kinase (BTK)-gene [1]. This defect leads to abnormal
development of B-lymphocytes and hypogammaglobuline-
mia. Patients with XLA usually present with recurrent
bacterial infections, mainly of the respiratory and gastrointes-
tinal tract. Other bacterial infections, like cellulitis, arthritis,
meningitis and sepsis have also been described, but are less
common. Various case reports mention a specific association
of XLA patients and patients with acquired hypogammaglo-
bulinemia with bacteremia caused by Helicobacter and
Campylobacter species (Table 1)[ 2, 3].
Recently, we treated a boy with XLA who developed
fever, loss of appetite and failure to thrive caused by a
combination of H. pylori gastritis and recurrent C. jejuni
bacteremia.
Case report
A 5-year-old Iranian boy with a history of recurrent
infections and an absence of peripheral blood B-
lymphocytes was diagnosed with XLA. The boy was living
in The Netherlands since his fifth year. DNA analysis
revealed a frame shift mutation (1614de1T) in exon 16 of
the BTK-gene [4]. He was treated with prophylactic co-
trimoxazole and intravenous immunoglobulin (IVIG) sub-
stitution therapy every 4 weeks. During the last 3 years,
IgG levels varied from 5.0 to 8.7 g/L (normal range for IgG
is 5.2–15.0 g/L). To reach a trough level of around 8 g/L he
required a high dosage of IVIG of 1.2 g/kg [5]. He had no
detectable IgA and IgM. At the age of 10 years he
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1316 Eur J Clin Microbiol Infect Dis (2010) 29:1315–1319developed epilepsy caused by left occipital lesions, pre-
sumably acquired by infections in the past.
At the age of 15 years he was admitted to our hospital
with progressive loss of appetite, initially ascribed to his
anti-epileptic medication. He was severely malnourished
(weight/length ratio −3 Dutch standard deviation score,
comparable to Iranian growth charts). Stool antigen test for
H. pylori was positive. Endoscopy and biopsies of the
gastric antrum, corpus and duodenum showed chronic
active inflammation with atrophy and intestinal metaplasia.
Cultures of the antrum and corpus were positive for H.
pylori as well as for C. jejuni. Biopsies of anthrum and
corpus were inoculated on non-selective blood agar media
and onto specific H. pylori media (Pylori agar, Biomérieux,
France) in a micro-aerophilic environment for 7 days.
Identification was performed by conventional biochemical
reactions according to standard operation procedures [6].
During hospitalization the patient had periods of fever.
Laboratory tests showed an elevated C-reactive protein (up
to 94 U/L; normal <5 U/L). His leukocyte and neutrophil
counts were always normal. Blood cultures revealed C.
jejuni, sensitive for ciprofloxacin (MIC 0.032 mg/L),
erythromycin (MIC 0.75 mg/L) and meropenem (MIC
0.012 mg/L) as determined by E-testing (AB Biomérieux,
Solna, Sweden). An identical strain was isolated from the
patient’s feces. Other pathogens were never detected from
stool, throat, urine or spinal fluid; cultures or PCR tests
were negative for enteric parasites, viruses including enter-
oviruses and pathogenic bacteria. The patient was treated
with intravenous meropenem for 2 weeks, followed by oral
erythromycin for another 4 weeks. Repeated blood cultures
after 10 days were negative. For eradication of H. pylori he
additionally received triple therapy with amoxicillin, clar-
ithromycin and omeprazol for one week. H. pylori was
sensitive to erythromycin (MIC 0.38 mg/L), clarithromycin
(MIC 0.19 mg/L) and meropenem (MIC 0.002 mg/L).
During follow-up he improved clinically and with tube
feeding his weight increased to −1 standard deviation score.
Endoscopy was repeated 8 months later and showed much
less inflammation of the gastric mucosa and absence of H.
pylori in microscopy and culture of biopsies. However,
from a fecal specimen a C. jejuni strain was isolated with
secondary resistance to erythromycin (MIC ≥ 256 mg/L)
but persistent sensitivity to ciprofloxacin (MIC 0.125 mg/L)
and meropenem (MIC 0.008 mg/L). Ten months later, he
again developed a C. jejuni bacteremia. The strain had a
similar pattern as the stool isolate, with high level resistance
to erythromycin by E-testing (MIC ≥ 256 mg/L), but the
strain was sensitive to tetracycline. Sequence analysis of
part of the 23S rRNA gene revealed an A2058C mutation
(position of nucleotide reported as the Escherichia coli
equivalent), known to be associated with erythromycin
resistance [7, 8]. The strain isolated 8 weeks earlier from
the feces did not have this mutation. No other pathogens
were isolated. He again had complaints of loss of appetite,
no diarrhea or skin lesions and some weight loss. Co-
trimoxazole prophylactic therapy was switched to azithro-
mycin (for 2 weeks) and later to doxycycline (for 4 weeks),
which resulted in clinical improvement and negative stool
and blood cultures at follow-up after 6 months.
Discussion
In the primary antibody deficiency disorders such as XLA,
enteropathogenic Helicobacter species and the closely
related species Flexispira and Campylobacter can cause
persistent gastrointestinal infections and bacteremia, as well
as skin and bone infections [2, 3, 9, 10]. In immunocom-
petent individuals bacteria are eliminated from the blood by
antibody- and complement-mediated lysis. Patients with
XLA form no or inadequate specific antibodies [1, 11].
Despite immunoglobulin substitution therapy with normal
IgG levels (IgA and IgM antibodies remained absent),
severe infections with Campylobacter and Helicobacter can
emerge [11]. Higher IgG through levels during immuno-
globulin supplementation may lead to better protection [5].
In the Netherlands the incidence of Campylobacter
infections is 39 per 100,000 people per year (children and
adults) [12]. C. jejuni is the most frequently isolated
pathogen of the Campylobacter species; C. coli, C. lari
and C. upsaliensis are less frequently encountered patho-
gens. Transmission of C. jejuni occurs by ingestion of
contaminated food (i.e. chicken and pork), water and
unpasteurized milk. Helicobacter infections in children are
acquired early in life, mainly via oral–fecal contact. In the
Netherlands, the prevalence of H. pylori in children is very
low (1.2%); most infected children are offspring of non-
Dutch parents like our patient [13]. Our patient had a
double infection, which may be coincidental but could also
be based on his Iranian background. In Iran, the prevalence
of H. pylori was reported to be 58% in healthy 15-year-old
children [14].
Bacteremia with Campylobacter and Helicobacter spe-
cies is frequently found in XLA patients. Winkelstein et al.
[2] found a prevalence of 10% in 21 septicemic patients
from a series of 201 XLA patients. Recognition of
bacteremia with Helicobacter and Campylobacter species
is sometimes difficult, since Helicobacter and Campylo-
bacter grow slowly in standard automatic blood culture
systems. It is recommended to subculture blood culture
bottles to solid media after one week of incubation when no
signal of growth has appeared. In some microbiological
laboratories this is a standard procedure for blood culture
bottles from patients with endocarditis or from patients with
hypogammaglobulinemia. In our patient the standard blood
Eur J Clin Microbiol Infect Dis (2010) 29:1315–1319 1317cultures were negative; only subculturing resulted in
recognition of C. jejuni.
Symptoms, antibiotic treatment, antibiotic resistance,
and duration of bacteremia of published cases are summa-
rized in Table 1. Twenty-six immunocompromised patients
with bacteremia caused by Campylobacter or Helicobacter
species have been described in the literature; only five of
these cases were children (<18 years of age). Remarkably,
diarrhea or other gastrointestinal complaints are not always
present (33–37%) [9]. Erysipelas-like cellulitis was present
in 11 of 26 patients (40%); it mostly disappears within
several days after start of antibiotic therapy but is an
important early clinical sign for Helicobacter or Campylo-
bacter bacteremia. Five of 25 patients (20%) had septic
arthritis or osteomyelitis, which is remarkably high; others
described an incidence of, respectively, 7% and 3% in 201
patients with XLA [2].
Most patients needed prolonged antibiotic therapy to
eradicate the microorganisms, with a mean duration of
approximately 10 months (ranging from 1 week to 3 years).
Our patient presented with fever, malaise and anorexia. He
had a long lasting and recurrent bacteremia, which almost
exclusively appears in immunocompromised patients.
In immunocompetent individuals, H. pylori remains a
superficial chronic gastritis, with a small percentage of
individuals progressing to duodenal or gastric ulcers and
rarely to gastrointestinal malignancies. Common variable
immunodeficiency patients have an almost 50-fold in-
creased risk for gastric cancer and a 30-fold increased risk
for lymphoma [11]. The patient we described did not
develop a relapse or recurrent H. pylori infection.
Antibiotic resistance of Campylobacter species to fluo-
roquinolones and macrolides is increasing. In The Nether-
lands, resistance to fluoroquinolones and macrolides is up
to 35% and 2.7% of the isolates, respectively [12].
However, the latter may be overestimated, since phenotyp-
ical routine susceptibility tests for erythromycin are difficult
to interpret [15]. Most Campylobacter isolates are sensitive
for amoxicillin-clavulanic acid (resistance rate 1–2%) [9].
The strain of our patient had high-level resistance to
erythromycin (MIC ≥ 256 mg/L). Because of reported
difficulties in the phenotypic recognition of erythromycin
resistant isolates, the presence of the erythromycin resistant
C. jejuni was confirmed by 23S rRNA gene sequence;
analysis revealed an A2058C mutation [7, 15]. Campylo-
bacter isolates displaying resistance to erythromycin usu-
ally have resistance-associated mutations at position 2058
and/or 2059 of the 23S rRNA gene. They lead to cross-
resistance to macrolide and lincosamide antibiotics. No
resistance has been described for carbapenem antibiotics,
such as meropenem [9].
The mortality of inadequately treated bacteremia is
estimated to be around 2.5–5.5% [9]. The mean duration
of treatment of bacteremia is 10 to 14 days in immuno-
competent individuals. In immunocompromised patients
longer treatment may be necessary. Also, in our patient the
Campylobacter was hard to eradicate. He received 2 weeks
intravenous treatment with meropenem, followed by 4
weeks erythromycin with apparently good effect. However,
despite changes of antibiotic treatment C. jejuni remained
detectable in his stool cultures, and later on he had a relapse
of bacteremia. After a 4-week course of doxycycline, C.
jejuni could be eradicated.
In conclusion, multiple infections can be encountered in
patients with XLA that present with vague symptoms such
as failure to thrive, weight loss or anorexia and fever.
Bacteremia with the Campylobacter species is hard to
detect and needs specific laboratory expertise. In patients
with agammaglobulinemia, Campylobacter eradication can
only be achieved with adequate antibiotic therapy and
prolonged treatment; H. pylori seems easier to eliminate.
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